The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Liver Diseases Therapeutics Market In 2026, And How Will Its Value Evolve By 2030?

The market size for liver diseases therapeutics has experienced robust growth in recent years. It is anticipated to expand from $15.18 billion in 2025 to $16.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. The historical growth can be mainly ascribed to the high prevalence of viral hepatitis infections, a rise in alcohol-induced liver disease cases, an initial reliance on antiviral and supportive therapies, the limited treatment options for chronic liver conditions, and the expansion of hospital-based liver care.

The liver diseases therapeutics market is projected to undergo significant growth in the forthcoming years. It is forecast to expand to $24.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.9%. This expansion over the forecast period is primarily driven by an increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, greater awareness regarding the benefits of early treatment, and increased healthcare spending on chronic liver conditions. Prominent trends expected during this period include a heightened demand for antiviral treatments in hepatitis management, a stronger focus on NAFLD and NASH management, the increasing utilization of immunotherapy for liver cancer, the broader application of combination drug therapies, and a rising emphasis on long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Significant Factors Are Influencing The Liver Diseases Therapeutics Market Expansion?

The increasing incidence of liver diseases is projected to boost the expansion of the liver disease therapeutics market moving forward. Liver disease refers to any condition affecting the liver, and liver disease therapeutics are employed to manage these conditions through various treatments. For instance, in December 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, premature deaths due to alcoholic liver disease escalated by 3.6%, reaching 5,984, up from 5,776 in 2022. Thus, the rising prevalence of liver diseases is a key factor driving the growth of the liver disease therapeutics market.

Which Segments Define The Liver Diseases Therapeutics Market Segment Structure?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

What Trends Are Affecting The Direction Of The Liver Diseases Therapeutics Market?

Major companies in the liver disease therapeutics market are increasingly prioritizing innovative technologies, such as artificial intelligence, to empower clinicians in identifying patients with liver fibrosis at early stages of disease progression. The application of artificial intelligence in liver disease therapeutics entails employing advanced computational algorithms and machine learning techniques to meticulously analyze medical data, thereby assisting in the prompt detection, precise diagnosis, and personalized treatment strategies for various liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT. This innovative AI-powered tool is designed to predict liver fibrosis in patients afflicted with chronic liver disease. Serving as a case-finding and cohort mapping instrument, it aims to pinpoint individuals susceptible to chronic liver disease (CLD). It operates as a secure, intuitive, and user-friendly system, capable of scrutinizing millions of data lines within seconds to identify patients who satisfy predefined criteria. Moreover, its capabilities include comprehensive data analysis, sophisticated machine learning algorithms, real-time risk stratification, and an easily navigable interface.

Who Are The Established Players Within The Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Get The Full Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Which Region Accounts For The Largest Portion Of The Liver Diseases Therapeutics Market?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Liver Diseases Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Market Report

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Fatty Liver Treatment Market Report

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.